WHO essential medicines that improve CKD outcomes should be widely available, including ACE inhibitors, angiotensin receptor blockers, statins and sodium glucose co-transporter-2 inhibitors (SGLT2i) [2, 39]. This evidence concerns the gene ACE and chronic kidney disease.